News | February 17, 2022
Asahi Kasei to build new filter assembly plant in Japan
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
